These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24771550)

  • 1. Liver graft allocation for hepatocellular carcinoma patients: is a forced ablate-and-wait protocol nationally applicable?
    Bazerbachi F; Aby E; Lake J
    Liver Transpl; 2014 May; 20(5):629-30. PubMed ID: 24771550
    [No Abstract]   [Full Text] [Related]  

  • 2. Selecting patients with hepatocellular carcinoma for liver transplantation: who should receive priority?
    Bazerbachi F; Aby E; Lake JR
    Liver Transpl; 2013 Dec; 19(12):1289-91. PubMed ID: 24214873
    [No Abstract]   [Full Text] [Related]  

  • 3. Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list.
    Mehta N; Dodge JL; Roberts JP; Hirose R; Yao FY
    Liver Transpl; 2014 May; 20(5):627-8. PubMed ID: 24493311
    [No Abstract]   [Full Text] [Related]  

  • 4. Donation after cardiac death in the hepatocellular carcinoma patient: Same indication?
    Vining CC; Ecker BL; Abt PL; Olthoff KM
    Liver Transpl; 2017 Oct; 23(S1):S27-S33. PubMed ID: 28846212
    [No Abstract]   [Full Text] [Related]  

  • 5. Is hepatic transplantation justified for primary liver cancer?
    Fisher RA; Maluf DG; Wolfe L; Williams B; Cotterell A; Stravitz RT; Heuman D; Posner M
    J Surg Oncol; 2007 Jun; 95(8):674-9. PubMed ID: 17477383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Liver transplantation for hepatocellular carcinoma].
    Decaens T; Hurtova M; Duvoux C
    Gastroenterol Clin Biol; 2009 Jan; 33(1 Pt 1):61-9. PubMed ID: 19108968
    [No Abstract]   [Full Text] [Related]  

  • 7. The Impact of Allocation Changes on Patients with Hepatocellular Carcinoma.
    Yohanathan L; Heimbach JK
    Clin Liver Dis; 2020 Nov; 24(4):657-663. PubMed ID: 33012451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
    Toso C; Dupuis-Lozeron E; Majno P; Berney T; Kneteman NM; Perneger T; Morel P; Mentha G; Combescure C
    Hepatology; 2012 Jul; 56(1):149-56. PubMed ID: 22271250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model for end-stage liver disease exceptions: proceed with caution.
    Washburn K
    Liver Transpl; 2011 Oct; 17(10):1123-4. PubMed ID: 21837739
    [No Abstract]   [Full Text] [Related]  

  • 10. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma.
    Wald C; Russo MW; Heimbach JK; Hussain HK; Pomfret EA; Bruix J
    Radiology; 2013 Feb; 266(2):376-82. PubMed ID: 23362092
    [No Abstract]   [Full Text] [Related]  

  • 11. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
    Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
    Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case 23-2005: a man with a mass in the liver.
    Smith AD; Morse MA; Kuo PC
    N Engl J Med; 2005 Nov; 353(20):2195-7; author reply 2195-7. PubMed ID: 16299939
    [No Abstract]   [Full Text] [Related]  

  • 13. Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts: how long should we wait?
    Kruel CR; Chedid AD; Grezzana-Filho TJ
    Transplantation; 2014 Jan; 97(2):e6. PubMed ID: 24434486
    [No Abstract]   [Full Text] [Related]  

  • 14. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply to "Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts: how long should we wait?".
    Chan SC
    Transplantation; 2014 Jan; 97(2):e6-7. PubMed ID: 24434487
    [No Abstract]   [Full Text] [Related]  

  • 16. Who should get a liver graft?
    Freeman RB; Jamieson N; Schaubel DE; Porte RJ; Villamil FG
    J Hepatol; 2009 Apr; 50(4):664-73. PubMed ID: 19233503
    [No Abstract]   [Full Text] [Related]  

  • 17. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates.
    Alver SK; Lorenz DJ; Marvin MR; Brock GN
    Liver Transpl; 2016 Oct; 22(10):1343-55. PubMed ID: 27343202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma.
    Smith AD; Dunk AA; Tuttle-Newhall JE; Trotter JF
    Lancet; 2004 Mar; 363(9412):898-9. PubMed ID: 15031047
    [No Abstract]   [Full Text] [Related]  

  • 19. Liver transplantation for hepatocellular carcinoma: is expansion of criteria justified?
    Roayaie S; Llovet JM
    Clin Liver Dis; 2005 May; 9(2):315-28. PubMed ID: 15831276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the treatment of hepatocellular carcinoma on the waiting list necessary?
    Majno P; Lencioni R; Mornex F; Girard N; Poon RT; Cherqui D
    Liver Transpl; 2011 Oct; 17 Suppl 2():S98-108. PubMed ID: 21954097
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.